Breast Density Notification Requirements After the MQSA Final Rule

For the first time in U.S. history, federal law requires every mammography facility to tell patients about their breast density. The requirement took effect with enforcement of the MQSA Final Rule on September 10, 2024, and it applies to every report and every patient summary, not just to women with dense tissue. This guide covers what you must include, the standardized language the FDA expects, and how to get the notification into patients' hands inside the same clock that governs results.

This article is general information, not legal advice. Confirm the exact required wording against current FDA guidance before you publish or mail anything.

What the breast density rule requires

Two things changed. First, every mammography report must now carry an overall assessment of breast density using one of four standardized categories. Second, the patient lay summary must tell the patient, in plain language, whether her breasts are dense or not dense, and point her to a conversation with her provider.

The four density categories the report must use are:

The breasts are almost entirely fatty.
There are scattered areas of fibroglandular density.
The breasts are heterogeneously dense, which may obscure small masses.
The breasts are extremely dense, which lowers the sensitivity of mammography.

Categories 3 and 4 are considered "dense." Patients in those categories get the dense-breast version of the notification; everyone else gets the not-dense version.

The standardized patient language

The FDA specified the exact wording facilities must use in the patient lay summary. For patients whose tissue is not dense, the required statement reads:

"Breast tissue can be either dense or not dense. Dense tissue makes it harder to find breast cancer on a mammogram and also raises the risk of developing breast cancer. Your breast tissue is not dense. Talk to your healthcare provider about breast density, risks for breast cancer, and your individual situation."

For patients with dense tissue, the required statement is identical except for the middle sentence:

"Breast tissue can be either dense or not dense. Dense tissue makes it harder to find breast cancer on a mammogram and also raises the risk of developing breast cancer. Your breast tissue is dense. Talk to your healthcare provider about breast density, risks for breast cancer, and your individual situation."

This is required language, not a suggestion. It is not a place to improvise. Lock both statements into your templates and keep them consistent across every letter.

Why this is an operational problem, not just a wording problem

The wording is published and fixed. The hard part is mechanical: every single patient summary now has to carry the correct density statement, matched to that patient's category, mailed inside the 30-day results window (and the 7-day window for suspicious findings). That is a per-patient, every-time requirement layered on top of the results and recall letters facilities were already sending.

Three things go wrong:

The wrong version goes out. A dense-breast patient receives the not-dense statement, or vice versa, because the letter template is not driven by the report's density category.
It is late. The density notification rides along with the results letter, so any delay in the results letter is also a compliance gap on density.
There is no record. If a question comes up later, the facility cannot show which version was sent, to whom, and when.

How to send density notifications correctly and on time

The reliable pattern is to generate the letter from the report data so the density category in the report selects the correct standardized statement automatically, mail it on the same fast cycle as the results letter, and keep a record of every send. Done by hand, this is exactly the kind of repetitive, high-stakes step where errors and delays creep in.

PatientLetterHub builds the density notification into the same results and recall letters it mails for you, pulling the correct standardized statement from the patient's density category, sent on time with a record of every notification. See how it works.

Frequently asked questions

When did the breast density notification requirement take effect? Enforcement began September 10, 2024, under the MQSA Final Rule. It is the first federal breast density notification standard.

Does the notification go to all patients or only those with dense breasts? All patients. Every summary must state whether the patient's breasts are dense or not dense.

Do we have to use the FDA's exact wording? Yes. The FDA published the specific statements the lay summary must contain, one for dense tissue and one for not-dense tissue. Lock both into your templates.

How many breast density categories are there? Four. The two denser categories (heterogeneously dense and extremely dense) are classified as "dense."